[go: up one dir, main page]

SE0401842D0 - Infusion and injection solution of levodopa - Google Patents

Infusion and injection solution of levodopa

Info

Publication number
SE0401842D0
SE0401842D0 SE0401842A SE0401842A SE0401842D0 SE 0401842 D0 SE0401842 D0 SE 0401842D0 SE 0401842 A SE0401842 A SE 0401842A SE 0401842 A SE0401842 A SE 0401842A SE 0401842 D0 SE0401842 D0 SE 0401842D0
Authority
SE
Sweden
Prior art keywords
levodopa
infusion
injection solution
metabolising enzyme
physiologically acceptable
Prior art date
Application number
SE0401842A
Other languages
English (en)
Inventor
Nil Dizdar Segrell
Bjoern Lindvall
Original Assignee
Dizlin Medical Design Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizlin Medical Design Ab filed Critical Dizlin Medical Design Ab
Priority to SE0401842A priority Critical patent/SE0401842D0/sv
Publication of SE0401842D0 publication Critical patent/SE0401842D0/sv
Priority to HK08101908.1A priority patent/HK1111347B/xx
Priority to EA200700020A priority patent/EA012415B1/ru
Priority to PT57570665T priority patent/PT1773297E/pt
Priority to BRPI0513293-2A priority patent/BRPI0513293A/pt
Priority to CN200580029688.5A priority patent/CN101022784B/zh
Priority to ZA200700993A priority patent/ZA200700993B/xx
Priority to EP10181105.7A priority patent/EP2298281B1/en
Priority to SI200531958T priority patent/SI1773297T1/sl
Priority to US11/631,602 priority patent/US20080255235A1/en
Priority to HRP20150384TT priority patent/HRP20150384T1/hr
Priority to PCT/SE2005/001135 priority patent/WO2006006929A1/en
Priority to DK05757066T priority patent/DK1773297T3/en
Priority to AU2005262918A priority patent/AU2005262918B2/en
Priority to JP2007521433A priority patent/JP2008505966A/ja
Priority to KR1020077003232A priority patent/KR20070042172A/ko
Priority to MX2013006111A priority patent/MX349829B/es
Priority to PL05757066T priority patent/PL1773297T3/pl
Priority to EP05757066.5A priority patent/EP1773297B1/en
Priority to CA2574437A priority patent/CA2574437C/en
Priority to ES05757066.5T priority patent/ES2534596T3/es
Priority to MX2007000406A priority patent/MX2007000406A/es
Priority to IL180650A priority patent/IL180650A/en
Priority to US13/208,628 priority patent/US8735382B2/en
Priority to JP2012183865A priority patent/JP2013028609A/ja
Priority to US14/251,967 priority patent/US9248113B2/en
Priority to CY20151100347T priority patent/CY1116197T1/el
Priority to JP2015126946A priority patent/JP2015227341A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0401842A 2004-07-12 2004-07-12 Infusion and injection solution of levodopa SE0401842D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0401842A SE0401842D0 (sv) 2004-07-12 2004-07-12 Infusion and injection solution of levodopa
MX2007000406A MX2007000406A (es) 2004-07-12 2005-07-08 Solucion para infusion e inyeccion de levodopa.
DK05757066T DK1773297T3 (en) 2004-07-12 2005-07-08 Infusion and injection solution of Levodopa
JP2007521433A JP2008505966A (ja) 2004-07-12 2005-07-08 レボドパの輸液および注射液
PT57570665T PT1773297E (pt) 2004-07-12 2005-07-08 Solução de perfusão e de injeção de levodopa
BRPI0513293-2A BRPI0513293A (pt) 2004-07-12 2005-07-08 solução de infusão ou injeção de levodopa, seringa descartável, e, cassete de bomba de infusão
CN200580029688.5A CN101022784B (zh) 2004-07-12 2005-07-08 左旋多巴输液和注射液
ZA200700993A ZA200700993B (en) 2004-07-12 2005-07-08 Infusion and injection solution of levodopa
EP10181105.7A EP2298281B1 (en) 2004-07-12 2005-07-08 Infusion and injection solution of Levodopa
SI200531958T SI1773297T1 (sl) 2004-07-12 2005-07-08 Infuzija in injiciranje raztopine Levodope
US11/631,602 US20080255235A1 (en) 2004-07-12 2005-07-08 Infusion and Injection Solution of Levodopa
HRP20150384TT HRP20150384T1 (hr) 2004-07-12 2005-07-08 Infuzijska i injekcijska otopina levodope
PCT/SE2005/001135 WO2006006929A1 (en) 2004-07-12 2005-07-08 Infusion and injection solution of levodopa
HK08101908.1A HK1111347B (zh) 2004-07-12 2005-07-08 左旋多巴輸液和注射液
AU2005262918A AU2005262918B2 (en) 2004-07-12 2005-07-08 Infusion and injection solution of Levodopa
EA200700020A EA012415B1 (ru) 2004-07-12 2005-07-08 Инфузионный и инъекционный раствор леводопа
KR1020077003232A KR20070042172A (ko) 2004-07-12 2005-07-08 레보도파의 주입 용액 및 주사 용액
MX2013006111A MX349829B (es) 2004-07-12 2005-07-08 Solucion para infusion e inyeccion de levodopa.
PL05757066T PL1773297T3 (pl) 2004-07-12 2005-07-08 Roztwór lewodopy do infuzji i iniekcji
EP05757066.5A EP1773297B1 (en) 2004-07-12 2005-07-08 Infusion and injection solution of levodopa
CA2574437A CA2574437C (en) 2004-07-12 2005-07-08 Infusion and injection solution of levodopa
ES05757066.5T ES2534596T3 (es) 2004-07-12 2005-07-08 Solución para infusión e inyección de levodopa
IL180650A IL180650A (en) 2004-07-12 2007-01-11 Levodopa solution for infusion and injection
US13/208,628 US8735382B2 (en) 2004-07-12 2011-08-12 Infusion and injection solution of levodopa
JP2012183865A JP2013028609A (ja) 2004-07-12 2012-08-23 レボドパの輸液および注射液
US14/251,967 US9248113B2 (en) 2004-07-12 2014-04-14 Infusion and injection solution of Levodopa
CY20151100347T CY1116197T1 (el) 2004-07-12 2015-04-09 Διαλυμα εγχυσης και ενεσης της λεβεντοπα
JP2015126946A JP2015227341A (ja) 2004-07-12 2015-06-24 レボドパの輸液および注射液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401842A SE0401842D0 (sv) 2004-07-12 2004-07-12 Infusion and injection solution of levodopa

Publications (1)

Publication Number Publication Date
SE0401842D0 true SE0401842D0 (sv) 2004-07-12

Family

ID=32867227

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401842A SE0401842D0 (sv) 2004-07-12 2004-07-12 Infusion and injection solution of levodopa

Country Status (21)

Country Link
US (3) US20080255235A1 (sv)
EP (2) EP2298281B1 (sv)
JP (3) JP2008505966A (sv)
KR (1) KR20070042172A (sv)
CN (1) CN101022784B (sv)
AU (1) AU2005262918B2 (sv)
BR (1) BRPI0513293A (sv)
CA (1) CA2574437C (sv)
CY (1) CY1116197T1 (sv)
DK (1) DK1773297T3 (sv)
EA (1) EA012415B1 (sv)
ES (1) ES2534596T3 (sv)
HR (1) HRP20150384T1 (sv)
IL (1) IL180650A (sv)
MX (2) MX349829B (sv)
PL (1) PL1773297T3 (sv)
PT (1) PT1773297E (sv)
SE (1) SE0401842D0 (sv)
SI (1) SI1773297T1 (sv)
WO (1) WO2006006929A1 (sv)
ZA (1) ZA200700993B (sv)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CN102438587B (zh) * 2009-05-19 2015-08-19 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物
MX348225B (es) 2010-11-15 2017-05-31 Neuroderm Ltd Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
KR20140035325A (ko) * 2010-12-10 2014-03-21 신애질 코포레이션 피하의 불용융성 레보도파 프로드러그 조성물들 및 주입 방법들
DK3533447T3 (da) * 2012-03-20 2023-04-24 Eagle Pharmaceuticals Inc Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse
EA032344B1 (ru) * 2012-05-10 2019-05-31 ЭйОуПи ОРФАН ФАРМАСЬЮТИКАЛС АГ Применение готового для использования состава, содержащего раствор эсмолол гидрохлорида, и способ лечения
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
CA2888979A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics, Inc. Reducing inter-patient variability of levodopa plasma concentrations
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20150182688A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
US20150182697A1 (en) * 2013-12-31 2015-07-02 Abbvie Inc. Pump, motor and assembly for beneficial agent delivery
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HUE064818T2 (hu) 2014-03-13 2024-04-28 Neuroderm Ltd Dopa dekarboxiláz inhibitor készítmények
BE1022042B1 (nl) 2014-09-29 2016-02-08 Puratos Nv Verbeterde cakebeslagsoorten
KR20180004756A (ko) 2015-05-06 2018-01-12 신애질 코포레이션 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법
CA3019178A1 (en) 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
EP4445953A3 (en) * 2017-06-05 2025-01-29 Dizlin Pharmaceuticals AB Levodopa infusion solution
RU2676761C1 (ru) * 2017-10-09 2019-01-11 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Полиионный инфузионный раствор
EP3806642A1 (en) 2018-06-12 2021-04-21 Novozymes A/S Less added sugar in baked products
AU2019379806A1 (en) 2018-11-15 2021-05-27 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
JP2023547460A (ja) 2020-11-02 2023-11-10 ノボザイムス アクティーゼルスカブ ペニシリウム属（ｐｅｎｉｃｉｌｌｕｍ）からの熱安定性ａｍｇ多様体を有する焼成品及び下焼き品
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
AU2022457030A1 (en) 2022-05-04 2024-11-07 Novozymes A/S Brewing with thermostable amg variants
AU2022476760A1 (en) 2022-09-01 2025-02-13 Novozymes A/S Baking with thermostable amyloglucosidase (amg) variants (ec 3.2.1.3) and low added sugar
AU2022476759A1 (en) 2022-09-01 2025-02-13 Novozymes A/S Baking with thermostable amg glucosidase variants (ec 3.2.1.3) and low or no added emulsifier
CN120091760A (zh) 2022-10-24 2025-06-03 诺维信公司 使用热稳定AMG变体和α-淀粉酶的烘焙方法
WO2024088550A1 (en) 2022-10-24 2024-05-02 Novozymes A/S Baking method for pulse protein fortified bread employing thermostable amyloglucosidase variante (ec 3.2.1.3)
CN120344150A (zh) 2022-11-30 2025-07-18 诺维信公司 用热稳定葡糖淀粉酶变体在低ph下烘焙
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5518688B2 (sv) * 1972-12-02 1980-05-21
JPS5537528B2 (sv) * 1972-12-11 1980-09-29
JPS54105221A (en) * 1978-02-02 1979-08-18 Sankyo Co Ltd Preparation of stable concentrated dopa injection
JPS6021570B2 (ja) * 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4850980A (en) * 1987-12-04 1989-07-25 Fisher Scientific Company I.V. pump cassette
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
SE512655C2 (sv) * 1993-11-17 2000-04-17 Medmera Sweden Hb C O Nil Dizd Infusionslösning för medicinskt bruk innehållande L-dopa
JP3865450B2 (ja) 1997-02-14 2007-01-10 田辺製薬株式会社 パーキンソニズム治療剤
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FI109453B (sv) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaceutisk komposition
DE10261808A1 (de) 2002-12-19 2004-07-08 Turicum Drug Development Ag Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen
WO2005023185A2 (en) 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa

Also Published As

Publication number Publication date
US20110294889A1 (en) 2011-12-01
CA2574437C (en) 2014-08-19
IL180650A (en) 2016-10-31
ZA200700993B (en) 2008-08-27
CA2574437A1 (en) 2006-01-19
KR20070042172A (ko) 2007-04-20
CY1116197T1 (el) 2017-02-08
JP2015227341A (ja) 2015-12-17
PT1773297E (pt) 2015-05-05
EA012415B1 (ru) 2009-10-30
DK1773297T3 (en) 2015-04-20
ES2534596T3 (es) 2015-04-24
EA200700020A1 (ru) 2007-08-31
MX349829B (es) 2017-08-15
HRP20150384T1 (hr) 2015-06-19
US20140221489A1 (en) 2014-08-07
SI1773297T1 (sl) 2015-07-31
HK1111347A1 (zh) 2008-08-08
US9248113B2 (en) 2016-02-02
CN101022784B (zh) 2016-02-24
EP2298281A1 (en) 2011-03-23
BRPI0513293A (pt) 2008-05-06
CN101022784A (zh) 2007-08-22
EP1773297B1 (en) 2015-01-14
JP2008505966A (ja) 2008-02-28
MX2007000406A (es) 2007-06-25
JP2013028609A (ja) 2013-02-07
PL1773297T3 (pl) 2015-08-31
US20080255235A1 (en) 2008-10-16
EP2298281B1 (en) 2019-04-24
US8735382B2 (en) 2014-05-27
EP1773297A1 (en) 2007-04-18
AU2005262918B2 (en) 2010-12-23
WO2006006929A1 (en) 2006-01-19
IL180650A0 (en) 2007-06-03
AU2005262918A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
SE0401842D0 (sv) Infusion and injection solution of levodopa
EP2594563A3 (en) 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
PT896538E (pt) Utilizacao de efectores da dipeptidilpeptidase iv que diminuem a sua actividade para baixar o teor em glucose no sangue em mamiferos
MY152172A (en) Therapeutic agent for diabetes
WO2007135182A3 (en) Factor ix analogues having prolonged in vivo half life
MXPA05006634A (es) Fluidos de dialisis biocompatibles que contienen icodextrinas.
WO2006044531A3 (en) Antisense modulation of ptp1b expression
ES2334258T3 (es) Control de la glucosa en sangre en el tratamiento de la diabetes que usa la insulina administrada pulmonarmente en combinacion con la insulina basal.
NO20051161L (no) Azulenderivater og salter derav
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
MY141034A (en) Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use
NZ603614A (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
ATE344049T1 (de) Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
UA91137C2 (ru) Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения
WO2008133157A1 (ja) 体温低下抑制剤
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
MXPA04008195A (es) Metodos para el tratamiento de la diabetes empleando inhibidores de pde11a.
WO2000047721A3 (en) Methods of inducing insulin positive progenitor cells